James Chih Hsin Yang

Summary

Affiliation: National Taiwan University
Country: Taiwan

Publications

  1. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
  2. pmc The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
    Byoung Chul Cho
    Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Yonsei Med J 51:1-8. 2010
  3. doi request reprint Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)
    James Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan Electronic address
    Lung Cancer 83:174-81. 2014
  4. pmc Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors
    Chia Lin Hsu
    Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan
    BMC Cancer 12:241. 2012
  5. doi request reprint Diarrhea associated with afatinib: an oral ErbB family blocker
    James Chih Hsin Yang
    Graduate Institute of Oncology and Cancer Research Center, National Taiwan University Hospital, Taipei, Taiwan
    Expert Rev Anticancer Ther 13:729-36. 2013
  6. doi request reprint Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
    Chee Khoon Lee
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    J Natl Cancer Inst 105:595-605. 2013
  7. doi request reprint Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 26:2745-53. 2008
  8. doi request reprint EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
    Chih Hsin Yang
    Graduate Institute of Clinical Medicine, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Lung Cancer 60:S23-30. 2008
  9. doi request reprint Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taiwan
    Clin Lung Cancer 11:257-63. 2010
  10. doi request reprint Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Thorac Oncol 5:1424-9. 2010

Collaborators

Detail Information

Publications72

  1. pmc INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
    Yi long Wu
    Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
    BMC Cancer 11:430. 2011
    ..East-Asian ethnicity is an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a higher incidence of EGFR mutations among this patient population...
  2. pmc The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
    Byoung Chul Cho
    Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Yonsei Med J 51:1-8. 2010
    ..In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting...
  3. doi request reprint Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)
    James Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan Electronic address
    Lung Cancer 83:174-81. 2014
    ....
  4. pmc Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors
    Chia Lin Hsu
    Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan
    BMC Cancer 12:241. 2012
    ..We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC)...
  5. doi request reprint Diarrhea associated with afatinib: an oral ErbB family blocker
    James Chih Hsin Yang
    Graduate Institute of Oncology and Cancer Research Center, National Taiwan University Hospital, Taipei, Taiwan
    Expert Rev Anticancer Ther 13:729-36. 2013
    ....
  6. doi request reprint Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
    Chee Khoon Lee
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
    J Natl Cancer Inst 105:595-605. 2013
    ..We examined the impact of EGFR-tyrosine kinase inhibitors (TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients with and without EGFR mutations...
  7. doi request reprint Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 26:2745-53. 2008
    ..To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment...
  8. doi request reprint EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
    Chih Hsin Yang
    Graduate Institute of Clinical Medicine, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Lung Cancer 60:S23-30. 2008
    ..In addition, the presence of EGFR mutations is a useful tool to determine NSCLC patients' prognosis; some studies suggested that this may apply if patients are receiving first-line chemotherapy, not only if they are receiving EGFR-TKIs...
  9. doi request reprint Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taiwan
    Clin Lung Cancer 11:257-63. 2010
    ..To clarify the effectiveness of cetuximab after failure of gefitinib treatment, we investigated the clinical features of patients with NSCLC who received cetuximab-containing chemotherapy after failure of gefitinib...
  10. doi request reprint Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Thorac Oncol 5:1424-9. 2010
    ....
  11. doi request reprint Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors
    Kuan Yu Chen
    Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    J Thorac Oncol 5:82-9. 2010
    ..This study is to characterize the treatment modalities and outcomes for octogenarians with advanced NSCLC and to investigate the impact of EGFR-TKI on survival...
  12. ncbi request reprint Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei, 100 Taiwan
    Invest New Drugs 25:77-84. 2007
    ..Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC...
  13. ncbi request reprint Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
    Jin Yuan Shih
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Int J Cancer 118:963-9. 2006
    ..03). In conclusion, EGFR mutation analysis is feasible in needle biopsy/aspiration paraffin-fixed specimens. EGFR mutation is an independent predictor of gefitinib response and survival in patients of advanced NSCLC treated by gefitinib...
  14. doi request reprint Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:4877-82. 2008
    ..To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib, we investigated the clinical features of lung cancer in patients with exon 20 mutations and analyzed the gefitinib treatment response...
  15. ncbi request reprint A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
    Chia Chi Lin
    Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Anticancer Res 27:641-5. 2007
    ..Weekly paclitaxel and infusional high-dose 5-fluorouracil/leucovorin (HDFL) are both effective regimens for metastatic breast cancer (MBC) patients...
  16. doi request reprint Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
    Shang Gin Wu
    Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University Hospital, Yun Lin branch, Yun Lin, Taiwan
    Lung Cancer 72:333-9. 2011
    ..013) and EGFR mutations (p=0.021) had a longer PFS. In conclusion, lung adenocarcinoma patients receiving pemetrexed with EGFR mutations have a better response rate and longer PFS than those with wild type EGFR...
  17. doi request reprint Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response
    Chien Hung Gow
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:162-8. 2008
    ..To elucidate the role of EGFR mutations in radiation treatment, we evaluated the clinical response to WBRT and survival of lung adenocarcinoma patients with brain metastases...
  18. ncbi request reprint Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment
    Chih Hsin Yang
    Department of Oncology and Cancer Research Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Oncology 68:350-5. 2005
    ..A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients...
  19. doi request reprint First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, No 7 Chung Shan South Road, Taipei 10002, Taiwan
    Am J Respir Crit Care Med 178:847-53. 2008
    ..Deletions in exon 19 and L858R in exon 21 are the best-documented EGFR mutations that are associated with effective gefitinib responsiveness...
  20. doi request reprint Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial
    Chih Hsin Yang
    Graduate Institute of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Thorac Oncol 5:688-95. 2010
    ....
  21. ncbi request reprint Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
    Chia Chi Lin
    Department of Oncology, National Taiwan University, Taipei, Taiwan, ROC
    Anticancer Drugs 18:703-8. 2007
    ..3 and 8.9 months (range 1-50+), respectively. Twice-weekly TP-HDFL has the activity and toxicity profile similar to the previously reported same three-drug combination for advanced esophageal cancer...
  22. ncbi request reprint Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
    Cancer Res 65:6943-9. 2005
    ..Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins...
  23. ncbi request reprint Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
    Zhong Zhe Lin
    Department of Oncology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
    Lung Cancer 60:215-21. 2008
    ..Combinations of gemcitabine and paclitaxel with various doses and schedules were shown to be effective treatment for these patients. Nevertheless, the survival outcome of these patients is not clear...
  24. ncbi request reprint Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial
    Chiun Hsu
    Department of Oncology, National Taiwan University Hospital, 7, Chung Shan South Road, Taipei, 100, Taiwan
    Lung Cancer 62:334-43. 2008
    ....
  25. ncbi request reprint Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    James Chih Hsin Yang
    James Chih Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan Vera Hirsh, McGill University, Montreal, Quebec, Canada Martin Schuler, West German Cancer Center, University Duisburg Essen, Essen Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan Kenneth J O Byrne, St James Hospital, Dublin, Ireland Tony S K Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell Michael Palmer, Keele University, Keele, United Kingdom and Lecia V Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    J Clin Oncol 31:3342-50. 2013
    ..Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed...
  26. doi request reprint Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
    Wei Yu Liao
    Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Clin Lung Cancer 14:418-24. 2013
    ..To assess the efficacy and potential prognostic factors of patients with stage III N2 non-small-cell lung cancer (NSCLC) treated with neoadjuvant docetaxel-cisplatin (DP) chemotherapy followed by surgical resection...
  27. doi request reprint Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma
    Chun Ta Huang
    Department of Internal Medicine, National Taiwan University Hospital, Yun Lin Br, Yun Lin County, Taiwan
    Med Oncol 27:9-15. 2010
    ..Thus, in this study, we hypothesize that there exist correlations between EGFR mutation status and [(18)F]FDG uptake of advanced lung adenocarcinoma...
  28. pmc Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study
    Zhong Zhe Lin
    Department of Oncology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 10002, Taiwan
    Oncologist 17:1294-302. 2012
    ..This study examines the survival impact of platinum-based adjuvant chemotherapy for Asian patients with stage I-IIIA NSCLC...
  29. doi request reprint Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
    Shang Gin Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Oncologist 13:1276-84. 2008
    ..However, not all EGFR mutations have similarly high clinical response rates. This study aimed to investigate the clinical characteristics and response to gefitinib in lung adenocarcinoma patients with complex EGFR mutations...
  30. ncbi request reprint Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
    Jo Pai Chen
    Department of Oncology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
    Lung Cancer 60:92-7. 2008
    ..It should be given cautiously in elderly patients and in patients with chronic viral hepatitis or low white blood cell counts...
  31. doi request reprint Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
    Yu Yun Shao
    Department of Oncology, National Taiwan University Hospital, 7, Chung Shan S Rd, Taipei 10002, Taiwan
    Eur J Cancer 49:106-14. 2013
    ..The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the present study was to compare their efficacies in this population...
  32. doi request reprint Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 17:3812-21. 2011
    ..Patients and Methods: Specimens from 1,261 patients were tested for EGFR mutations. We surveyed the clinical data and the effectiveness of gefitinib and erlotinib in NSCLC patients with uncommon EGFR mutations...
  33. ncbi request reprint Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
    Wei Chu Chie
    School of Public Health and Graduate Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
    Qual Life Res 13:257-62. 2004
    ..The questionnaires could also detect expected adverse effects of radiotherapy, cisplatin, and paclitaxel...
  34. ncbi request reprint Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy
    Chao Chi Ho
    Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan, Republic of China
    Lung Cancer 59:105-10. 2008
    ..003) and OS (P=0.008), respectively. Caveolin-1 expression significantly correlated with drug resistance and a poor prognosis in advanced NSCLC patients treated with gemcitabine-based chemotherapy...
  35. doi request reprint Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
    Pei Fang Wu
    National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No 7, Chung Shan South Rd, Taipei, 100, Taiwan
    J Neurooncol 115:61-70. 2013
    ..Our study results showed that high membranous/cytoplasmic pIGF1R expression in brain metastases was a poor prognostic factor, more significantly in patients with EGFR mutations than in those with wild-type EGFRs. ..
  36. ncbi request reprint Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone
    Chih Hsin Yang
    Department of Oncology, Cancer Research Center, National Taiwan University Hospital, Medical College, National Taiwan University, Taipei, Taiwan
    Anticancer Res 23:2519-23. 2003
    ..In addition, topotecan efflux was markedly enhanced in the resistant cells. To investigate the possibility that novobiocin may enhance cytotoxicity in BCRP/MXR/ABCP overexpressing cells, we exposed MCF7/TPT300 cells to novobiocin...
  37. ncbi request reprint Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
    Jih Hsiang Lee
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Formos Med Assoc 109:338-44. 2010
    ..The purpose of this study was to evaluate the efficacy and safety of pemetrexed for heavily pretreated, advanced NSCLC...
  38. ncbi request reprint Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China
    Cancer 107:1873-82. 2006
    ..The survival outcome and the predictors for antitumor activity in chemonaive patients who received gefitinib as first-line treatment are unclear...
  39. pmc Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
    Zhong Zhe Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
    PLoS ONE 8:e80276. 2013
    ..However, the survival advantage of RFA needs confirmation in daily practice...
  40. doi request reprint Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
    Wei Yu Liao
    Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    J Thorac Oncol 7:973-81. 2012
    ....
  41. doi request reprint Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
    James Chih Hsin Yang
    Graduate Institute of Oncology and Cancer Research Centre, College of Medicine, National Taiwan University, Taipei, Taiwan
    Lancet Oncol 13:539-48. 2012
    ..Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations...
  42. doi request reprint EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR
    Shang Gin Wu
    Department of Internal Medicine, National Taiwan University Hospital Yun Lin Branch, Yun Lin, Taiwan
    J Thorac Oncol 7:98-104. 2012
    ..To understand the impact of EML4-ALK on the prognosis of non-small cell lung cancer, we examined EML4-ALK fusion in lung adenocarcinoma from patients with wild-type EGFR and analyzed their clinical treatment outcomes...
  43. ncbi request reprint Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions
    Yu Yun Shao
    Department of Oncology, National Taiwan University Hospital, Taipei 10002, Taiwan
    J Formos Med Assoc 109:362-8. 2010
    ..Hypersensitivity reactions during oxaliplatin infusion are a major problem associated with its use. In this study, we investigated the characteristics and risk factors of these events...
  44. ncbi request reprint Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer
    Yu Yun Shao
    Department of Oncology, National Taiwan University Hospital Yunlin Branch, 360 Xingzhong, Yunlin, Taipei, Taiwan
    Discov Med 9:538-45. 2010
    ..The adequate-powered, direct comparisons of gefitinib against erlotinib under the same clinical scenarios are lacking. There is no evidence at present that the efficacy of these two agents in NSCLC is different...
  45. doi request reprint High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
    Reury Perng Perng
    Chest Department, Taipei Veterans General Hospital, School of Medicine, National Yang Ming University, Taipei, Taiwan
    Lung Cancer 62:78-84. 2008
    ..An open label phase II study was conducted in Taiwanese patients with NSCLC to evaluate its efficacy...
  46. ncbi request reprint Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
    Hsiang Fong Kao
    Department of Oncology, National Taiwan University Hospital, Yun Lin branch, Yun Lin, Taiwan
    Support Care Cancer 22:1189-97. 2014
    ..To evaluate the preventive effects of topical skin disinfection with chlorhexidine on bloodstream infection (BSI) associated with totally implantable venous port (Port-A)...
  47. doi request reprint First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments
    Bin Chi Liao
    Department of Internal Medicine, National Taiwan University Hospital Hsin Chu Branch, Hsinchu, Taiwan
    Drugs 73:357-69. 2013
    ..PFS was prolonged but OS was not. The recent development of novel irreversible EGFR TKIs, such as afatinib and dacomitinib, is also reviewed...
  48. doi request reprint Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR
    Kuei Pin Chung
    Department of Laboratory Medicine, Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Clin Cancer Res 18:3470-7. 2012
    ..It is unknown if deletions occurring at different amino acid positions or of different sizes are associated with different clinical outcome to EGFR tyrosine kinase inhibitors (TKI)...
  49. doi request reprint ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Cheng Po Huang
    Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
    Cancer Lett 328:144-51. 2013
    ..These findings collectively suggest that ALDH1A1 positivity in cancer stem cells confers resistance to EGFR TKI in lung cancer...
  50. ncbi request reprint Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in Taiwan
    Reury Perng Perng
    Chest Department, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
    Jpn J Clin Oncol 37:9-15. 2007
    ..There is neither a nation-wide nor a large-scale, multi-institutional lung cancer database available for stage-by-stage survival analysis in Taiwan at present...
  51. doi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Rd, Taipei, 10002, Taiwan
    Target Oncol 4:37-44. 2009
    ..This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC...
  52. doi request reprint O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
    Pei Fang Wu
    Graduate Institute of Clinical Medicine, National Taiwan University, College of Medicine, Taipei, Taiwan
    Lung Cancer 68:484-90. 2010
    ..5 versus 3.5 months, P<0.001). In conclusion, MGMT expression was enhanced in brain metastases as compared with the primary lung cancers. MGMT expression in brain metastases was significantly correlated with better survival...
  53. doi request reprint Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
    Tzu Hsiu Tsai
    Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan Electronic address
    Lung Cancer 82:420-5. 2013
    ..We evaluated the feasibility of multi-gene analyses from waste brushing samples obtained by EBUS-assisted bronchoscopy...
  54. doi request reprint EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
    Chin Lun Huang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Lung Cancer 64:346-51. 2009
    ..Skin rash is the most common toxicity of epidermal growth factor receptor (EGFR)-targeted therapy. This study investigated the clinical and genetic factors associated with this skin rash...
  55. ncbi request reprint Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status
    Wen Pin Su
    Department of Oncology, National Taiwan University Hospital, Taipei
    J Formos Med Assoc 104:557-62. 2005
    ..However, most studies have only investigated patients who have good performance status or are evaluable. This study evaluated the efficacy of geftinib in a consecutive series of patients with NSCLC...
  56. doi request reprint EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Hsiang Fong Kao
    Department of Oncology, National Taiwan University Hospital Yun Lin Branch, Yun Lin, Taiwan
    Future Oncol 9:991-1003. 2013
    ....
  57. doi request reprint Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
    Kang Yi Su
    Institute of Statistical Science, Academia Sinica, Taipei, Taiwan
    J Clin Oncol 30:433-40. 2012
    ..This study used highly sensitive methods to detect T790M before and after TKI therapy and investigated the association of T790M and its mutation frequencies with clinical outcome...
  58. doi request reprint Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Drugs 71:79-88. 2011
    ..The results of these studies have led to a paradigm shift in the treatment of patients with advanced NSCLC. NSCLC with EGFR mutations constitutes a new entity requiring different personalized treatment strategies...
  59. doi request reprint Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
    Chia Chi Lin
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    Urol Oncol 26:659-61. 2008
    ..Arsenic trioxide in this dose and schedule can cause acute encephalopathy in patients with metastatic urothelial carcinoma who have received previous chemotherapy...
  60. ncbi request reprint Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
    Sung Hsin Kuo
    Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, No 7, Chung Shan South Rd, Taipei, Taiwan
    Lung Cancer 48:275-80. 2005
    ..36; progression-free survival: P=0.57). Our data suggest that the survival of patients who received chemotherapy but did not participate in clinical trials was similar to patients participated in clinical trials...
  61. doi request reprint Survival of patients with small cell lung carcinoma in Taiwan
    Yu Hsuan Kuo
    Department of Oncology, National Taiwan University Hospital Yun Lin Branch, Yunlin, Taiwan, ROC
    Oncology 82:19-24. 2012
    ..The prognosis for SCLC patients remains unsatisfactory despite advances in chemotherapy. In this study, we sought to clarify the prognosis and treatment patterns of patients with SCLC...
  62. doi request reprint MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
    Ming Hung Huang
    Graduate Institute of Oncology and Cancer Research Center, National Taiwan University, Taipei, Taiwan
    Mol Oncol 7:112-20. 2013
    ..Combined treatment of gefitinib and MEK inhibitors may be therapeutically useful for acquired gefitinib-resistance lung adenocarcinoma cells harboring EGFR mutations...
  63. ncbi request reprint A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemi
    Chih Hung Hsu
    Department of Oncology, National Taiwan University Hospital, Cancer Research Center, National Taiwan University College of Medicine, Taiwan
    Anticancer Res 22:3621-7. 2002
    ....
  64. ncbi request reprint Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
    Yen Shen Lu
    Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Hepatogastroenterology 51:815-9. 2004
    ..In this study, we sought to clarify if the addition of Interferon-alpha2b to HTD regimen could further improve the control of advanced hepatocellular carcinoma...
  65. ncbi request reprint Vesicant-type reaction due to docetaxel extravasation
    Chun Hsuan Ho
    Acta Derm Venereol 83:467-8. 2003
  66. ncbi request reprint Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
    Chih Hsin Yang
    J Chin Med Assoc 68:160-1. 2005
  67. pmc MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    James Bean
    Human Oncology and Pathogenesis Program, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:20932-7. 2007
    ..Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib...
  68. ncbi request reprint Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment
    Chia Yu Chu
    Acta Derm Venereol 82:147-8. 2002
  69. ncbi request reprint Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study
    Alex Chang
    Johns Hopkins Singapore International Medical Centre, Singapore
    J Thorac Oncol 1:847-55. 2006
    ....
  70. ncbi request reprint Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
    Gee Chen Chang
    Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
    J Thorac Oncol 1:520-5. 2006
    ..However, these factors tend to be correlated with each other; it is not clear whether gender, smoking history, and adenocarcinoma histology were all independent predictors for response in East Asian populations...
  71. ncbi request reprint A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
    Yuh Min Chen
    Chest Department, Taipei Veterans General Hospital, School of Medicine, National Yang Ming University, Taiwan
    Lung Cancer 56:89-95. 2007
    ..The objective of this phase II study was to define the efficacy of an oral form of vinorelbine combined with cisplatin for first line treatment of advanced/metastatic NSCLC...
  72. ncbi request reprint Thoracic radiotherapy for stage IV non-small cell lung cancer
    Chun Ru Chien
    Radiother Oncol 78:110; author reply 110-1. 2006